Document:

Exhibit 10.10

 EXHIBIT 10.10 
  
  
 AGREEMENT 
  
 This agreement (hereinafter referred to as the “AGREEMENT”) by and between New
River Pharmaceuticals Inc., its predecessors, successors and assigns, a Virginia corporation having its principal place of business at The Governor Tyler, 1881 Grove Avenue, Radford, Virginia 24141 (hereinafter “NEW RIVER”), and Innovative
Technologies, L.L.C., its predecessors, successors and assigns, a Virginia corporation having its principal place of business at 15120 Industrial Park Road, Bristol, VA 24202-3710 (hereinafter referred to as “INNOVATIVE”), and Keith
Latham, his heirs, estates, successors, and assigns, who resides at 799 Barclay Drive, Abingdon, VA 24210 (hereinafter referred to as “LATHAM”) (hereinafter referred to collectively as the “PARTIES” or individually as the
“PARTY”) is entered into as of this 30th day of June, 2004 (hereinafter the “EFFECTIVE DATE”).
 
  
  
 RECITALS 
  
 WHEREAS, NEW RIVER and
INNOVATIVE and/or LATHAM are parties to previous contracts and other agreements including: a Settlement Agreement dated March 20, 2000; an Assignment dated the April 5, 2000; an Option Agreement dated the April 5, 2000; an Assignment of Technology
and Trademark Transfer Agreement dated March 1, 1998; and a Technology and Trademark Transfer Agreement dated June 15, 1995; 
  
 WHEREAS, the PARTIES wish to modify certain terms of the CONTRACTS; 
  
 WHEREAS, the PARTIES also wish to set forth, consistent with applicable law, any and all inventorship claims of INNOVATIVE or LATHAM with regard to certain patents and
pending applications that are being, or have been, prosecuted by NEW RIVER or that have been issued to NEW RIVER, as well as any future applications relating to the patents, the pending applications, or the subject matter claimed or disclosed in
such patents or pending applications (hereinafter collectively referred to as “PATENT RIGHTS”); and 
  
 WHEREAS, INNOVATIVE and LATHAM desire to covenant never to commence, prosecute, or pursue any claim, demand or cause of action relating to any PATENT RIGHTS and/or CONTRACTS. 
  
 NOW, THEREFORE, in consideration of the promises and the mutual covenants set forth herein,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the PARTIES agree as follows: 
  

 Page 1 of 8 

 Article 1 
 PAYMENT; ROYALTY; LICENSES; CONTRACTS; PATENT RIGHTS 
  
 1.1      Payment to INNOVATIVE and LATHAM 
  

	 	1.1.1	As consideration for this AGREEMENT, NEW RIVER hereby agrees to pay the sum of Two Hundred Thousand Dollars ($200,000.00), by wire transfer to INNOVATIVE and LATHAM, jointly,
upon execution of this AGREEMENT. 

  
 1.2      Royalty to INNOVATIVE and LATHAM 
  

	 	1.2.1	As additional consideration for this AGREEMENT, provided that INNOVATIVE and LATHAM are not then in breach of this AGREEMENT, NEW RIVER shall remit to INNOVATIVE and LATHAM,
jointly, a royalty of One Percent (1%) of any NET SALES (as defined below) on any NEW RIVER PRODUCT (as defined below). However, NEW RIVER’S obligation to pay royalties to INNOVATIVE and LATHAM shall cease and be fully paid-up (i) when the
aggregate of royalty payments to INNOVATIVE and LATHAM total One Million Dollars ($1,000,000.00), or (ii) on June 30, 2014, whichever shall first occur. The royalty payment under this Section shall be paid annually within Sixty (60) days following
the end of the calendar year for which royalties are due. 

  

	 	1.2.2	Should a controlling interest of the stock of NEW RIVER or substantially all of the assets of NEW RIVER be acquired by a third party prior to June 30, 2014, and if the
aggregate amount of One Million Dollars ($1,000,000.00) of royalties has not been paid to INNOVATIVE and LATHAM, NEW RIVER shall remit to INNOVATIVE and LATHAM the amount of One Million Dollars ($1,000,000.00) less the amount of any royalties
already paid to INNOVATIVE and LATHAM pursuant to this Agreement. 

  

	 	1.2.3	NEW RIVER has no obligation to pay any royalty payments to INNOVATIVE and LATHAM in excess of One Million Dollars ($1,000,000.00), or to pay any royalty payments upon sales
occurring after June 30, 2014, regardless of whether One Million Dollars ($1,000,000.00) in royalties has been paid as of that date. 

  

	 	1.2.4	NET SALES shall mean, with respect to a PRODUCT, the gross amount invoiced by NEW RIVER to unrelated third parties, including without limitation any sub-licensee, for the
PRODUCT in the country, less: 

  
 (a) trade, quantity and cash discounts allowed; 
  
 (b)
commissions, discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other allowances which effectively reduce the net selling price; 
  

(c) actual PRODUCT returns and allowances; 
  
 (d) that portion of the sales value associated with delivery systems; 
  

 Page 2 of 8 

 (e) any tax imposed on the production, sale, delivery or use of the PRODUCT, including, without
limitation, sales, use, excise or value added taxes; 
  
 (f)
allowance for distribution expenses; and 
  
 (g) any other
similar and customary deductions. 
  

	 	1.2.5	PRODUCT shall mean any NEW RIVER marketed drug product whether wholly owned by NEW RIVER or licensed in by NEW RIVER. However, in the event that the PRODUCT is subject to a
third party royalty agreement, the calculation of the One Percent (1%) royalty due to INNOVATIVE and LATHAM shall be based only on NEW RIVER’s proceeds from the PRODUCT and not the aggregate proceeds for both NEW RIVER and any third party.

  
 1.3      Licenses 
  

	 	1.3.1	As further consideration for this AGREEMENT, NEW RIVER hereby grants to INNOVATIVE and LATHAM a fully paid-up, irrevocable, non-exclusive, non-transferable, non-assignable,
worldwide license in the FIELD A (as defined below) to make, use, sell, offer to sell, have made, and import products and methods embodying or made in accordance with the inventions claimed in the following applications or patents which may issue
from the following applications: (i) U.S. 09/986,426, (ii) JP2000-603722, (iii) AU 37239/00, (iv) CA 2,367,042, (v) EP 00916076.3, (vi) PCT/US00/03717, (vii) PCT/US00/05693, (vi) 09/959,396, and (ix) U.S. 60/123,146. For purposes of this
non-exclusive license, FIELD A shall be limited to (i) the development and commercialization of drug products for the treatment of Parkinson’s Disease, including formulations with Levo-Dopa, and (ii) the preparation of cell culture media.

  

	 	1.3.2	As further consideration for this AGREEMENT, NEW RIVER also grants to INNOVATIVE and LATHAM a fully paid-up, irrevocable, non-exclusive, non-transferable, non-assignable,
worldwide license in FIELD B (as defined below) to make, use, sell, offer to sell, have made, and import products and methods embodying or made in accordance with the invention as claimed in the following patents: U.S. Patent 5,767,227, (ii) U.S.
Patent 5,910,569, and (iii) Canadian Patent 2,072,613. For purposes of this non-exclusive license, FIELD B shall be limited to thyroid hormone pathologies. 

  
 1.4      CONTRACTS 
  

	 	1.4.1	INNOVATIVE, LATHAM and NEW RIVER hereby agree to modify, and hereby do modify, the CONTRACTS such that INNOVATIVE and LATHAM forgo, relinquish and waive any and all rights
and benefits INNOVATIVE and LATHAM had, have, or may have under the CONTRACTS and release NEW RIVER from any obligation it may have to INNOVATIVE and LATHAM under the CONTRACTS. 

  

 Page 3 of 8 

	 	1.4.2	INNOVATIVE, LATHAM and NEW RIVER hereby agree that the modification of the CONTRACTS does not affect any rights that NEW RIVER had, has, or may have under the CONTRACTS and
that any and all rights and benefits that NEW RIVER had, has, or may have under the CONTRACTS remain in full effect pursuant to the terms of the CONTRACTS, and does not effect any obligation that INNOVATIVE and LATHAM have to NEW RIVER under the
CONTRACTS. 

  

	 	1.4.3	Nothing in this Agreement shall be deemed in any way to grant, transfer, or convey any license, right, or interest to INNOVATIVE or LATHAM in any patent or application
falling within the definition of PATENT RIGHTS, except as expressly provided in Section 1.3.1 and 1.3.2. 

  

	 	1.4.4	INNOVATIVE and LATHAM acknowledge that there is a risk that, subsequent to the execution of this AGREEMENT, they will discover, incur or suffer claims that were unknown or
unanticipated at the time this AGREEMENT was executed, and that arose from, or are based upon, or are related to the PATENT RIGHTS or CONTRACTS, which claims, if known upon execution of this AGREEMENT, might have materially affected their decision
to execute this AGREEMENT. INNOVATIVE and LATHAM hereby expressly assume the risk of such unknown and unanticipated claims and agree that this AGREEMENT applies to and covers any and all such claims. 

  

	 	1.4.5	As consideration for this AGREEMENT, INNOVATIVE and LATHAM hereby fully and unconditionally release, acquit and discharge NEW RIVER from any and all claims, debts, actions,
claims for relief, rights, damages, accountings of whatever nature, demands and liabilities, whether liquidated or unliquidated, contingent or non-contingent, known or unknown, foreseen or unforeseen, in any way arising out of the PATENT RIGHTS
and/or CONTRACTS. 

  

	 	1.4.6	INNOVATIVE and LATHAM hereby agree that they will not in any way challenge or contest in any forum or in any manner the validity or the enforceability of any intellectual
property rights of any patent or application falling within the definition of PATENT RIGHTS. 

  
 1.5      PATENT RIGHTS  
  

	 	1.5.1	The PARTIES expressly acknowledge that upon review of the PATENT RIGHTS, INNOVATIVE and/or LATHAM are inventors, consistent with applicable law, only with respect to patents
or applications related to the PATENT RIGHTS identified as the following: (i) U.S. 09/986,426, (ii) JP2000-603722, (iii) AU 37239/00, (iv) CA 2,367,042, (v) EP 00916076.3, (vi) U.S. 5,910,569, (vii) U.S. 5,767,227, (viii) CA 2,072,613, (ix)
PCT/US00/03717, (x) PCT/US00/05693, (xi) 09/959,396, and (xii) U.S. 60/123,146. 

  

	 	1.5.2	Notwithstanding the foregoing, if INNOVATIVE or LATHAM are determined by NEW RIVER, a court of competent jurisdiction, by the U.S. Patent and 

  

 Page 4 of 8 

 Trademark Office, or foreign patent office to be inventors related to any patent or patent application
relating to any of the PATENT RIGHTS, INNOVATIVE and LATHAM in consideration of the terms of this AGREEMENT, and other good and valuable consideration, receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto NEW RIVER, its
successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America (including its territories and dependencies) and all countries foreign thereto in and to said improvements, said
United States application, any other United States applications, including provisional, divisional, renewal, substitute, continuation, reexamination and reissue applications, based in whole or in part on said United States application or in whole or
in part on said improvements, any foreign applications, including international and regional applications, based in whole or in part on any of the aforesaid United States applications or in whole or in part on said improvements, and in and to any
and all letters patent, including extensions thereof, of any country which have been or may be granted on any of the aforesaid applications or on said improvements or any parts thereof. 
  

	 	1.5.3	INNOVATIVE and LATHAM hereby agree to execute without further consideration any further documents and instruments, to be prepared at New River’s sole expense, which may
be necessary, lawful and proper for applications or patents within the definition of PATENT RIGHTS or in the preparation or prosecution of any continuing, substitute, divisional, renewal, reexamination or reissue application or in any amendments,
extensions or interference proceedings, or other applications for patents of any region or country, that may be necessary to secure to NEW RIVER its interest and title in and to the PATENT RIGHTS or any parts thereof, and in and to said several
patents or any of them. 

  

	 	1.5.4	INNOVATIVE and LATHAM further represent that they have not and will not grant any right, title, license, or interest to make, use, sell, have made, or offer to sell any
product, method, or apparatus, covered by any patent or application falling within the definition of PATENT RIGHTS, to anyone except NEW RIVER. Further, INNOVATIVE and LATHAM represent that they have not and will not themselves make, use, sell, have
made, or offer to sell any product, method, or apparatus, covered by any patent falling within the definition of PATENT RIGHTS, except as provided in Section 1.3.1 and 1.3.2. 

  

	 	1.5.5	If requested by NEW RIVER or required by applicable law, INNOVATIVE and LATHAM will authorize and request the Director of the United States Patent and Trademark Office to
issue any and all letters patent which may be granted upon said United States applications, or upon said improvements or any parts thereof when granted, to NEW RIVER related to applications or patents within the definition of PATENT RIGHTS.

  

 Page 5 of 8 

 Article 2 
 MISCELLANEOUS 
  
 2.1      Neither INNOVATIVE nor LATHAM shall assign this AGREEMENT or any of the rights or obligations hereunder without the prior written consent of NEW RIVER and any attempted assignment shall be null
and void. Subject to the obligations of NEW RIVER to INNOVATIVE and LATHAM hereunder, NEW RIVER may assign this AGREEMENT or otherwise transfer its rights in the licenses hereunder without the consent of INNOVATIVE or LATHAM. 
  
 2.2      This AGREEMENT
constitutes the complete and exclusive statement of the agreement between the PARTIES, oral or written, relating to the subject matter of this AGREEMENT, and supersedes all prior agreements, negotiations, and understandings, oral or written, between
the PARTIES relating to the subject matter of this AGREEMENT. This AGREEMENT can only be modified by a written agreement signed by both PARTIES. 
  
 2.3      The PARTIES agree that it is not the intention of any PARTY to violate any statutory or
common law and that any provision of this AGREEMENT that is illegal, invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without invalidating
the remaining portions hereof or affecting the validity or enforceability of such provisions in any other jurisdiction. 
  
 2.4      Failure by any Party to enforce any provision of this AGREEMENT shall not be deemed a
waiver of that provision or of any other provision of this AGREEMENT. Any claim of waiver of any right, obligation, term or condition of this AGREEMENT and any claim that any provision of this AGREEMENT has been modified or amended shall be null and
void unless such waiver, modification or amendment is made in writing and signed by NEW RIVER and an authorized representative of INNOVATIVE and by LATHAM. 
  
 2.5      This AGREEMENT shall be construed and enforced in accordance with, and shall be governed by
the laws of Virginia without giving any effect to the provision, policies or principles thereof relating to choice or conflict of laws. 
  
 2.6      This AGREEMENT shall be binding on, and inure to the benefit of, the PARTIES, their heirs,
estates, successors and assigns. 
  
 2.7      The headings used in this AGREEMENT are not to be deemed part of this AGREEMENT, but are for convenience only and do not affect or limit the meaning of the language in a paragraph. 

 
 2.8      The PARTIES
shall notify each other in writing, by certified mail. 
  
 2.9      INNOVATIVE and LATHAM and their respective attorneys agree to keep confidential, and not to disclose to others, except to the their respective accountants and attorneys,
the 
  

 Page 6 of 8 

 terms and conditions of this AGREEMENT or the content of any negotiations, conversations or discussions
between either PARTY and its attorneys, that in any way relate to the settlement as set forth in this AGREEMENT. 
  
 2.10    INNOVATIVE, LATHAM and NEW RIVER shall be deemed to have drafted this AGREEMENT equally, such that
neither the AGREEMENT as a whole nor any specific provision of it shall be construed against a PARTY under the rule of contract construction whereby contracts are construed against the drafter. 
  
 2.11    In executing this
AGREEMENT, each member of each PARTY fully, completely and unconditionally acknowledges and agrees that (i) it has had an opportunity to consult with, and seek the advice of, counsel of duly licensed and competent attorneys and that it has executed
this AGREEMENT after independent investigation, voluntarily and without fraud, duress or undue influence, and (ii) it fully understands the terms of this AGREEMENT and expressly consents that this AGREEMENT be given full force and effect according
to each and every of its express terms and provisions. 
  
 2.12    This AGREEMENT will become binding and effective upon the exchange of facsimile copies of the required signatures. The PARTIES will thereafter exchange formal signed originals of the AGREEMENT for their
permanent records. 
  
  
  
  
  
 [This space is intentionally left blank.] 
  

 Page 7 of 8 

 IN WITNESS WHEREOF, the PARTIES hereto have caused this AGREEMENT to be executed and signed by their duly authorized
representatives on the day and year set forth below. 
  

			
	NEW RIVER PHARMACEUTICALS INC.
		
	By:	 	/S/ RANDAL J. KIRK
		
	Title:	 	CHAIRMAN/PRESIDENT/CEO
		
	Date:	 	7/1/04
	 	 	 

  
  

			
	INNOVATIVE TECHNOLOGIES, L.L.C.
		
	By:	 	/S/ KEITH R. LATHAM
		
	Title:	 	MANAGING MEMBER
		
	Date:	 	6/30/04
	 	 	 

  
  
  

			
	KEITH LATHAM
		
	By:	 	/S/ KEITH R. LATHAM
		
	Date:	 	6/30/04
	 	 	 

  

 Page 8 of 8Exhibit 4.1(K)

 EXHIBIT 4.1(k) 
  
 SMITHFIELD FOODS, INC. 
  
 AMENDMENT AGREEMENT NO. 5 
  
 As of March 25, 2004 
  
 To each of the Current Holders 
 listed in Annex 1 attached hereto 

 
 Ladies and Gentlemen: 
  
 Smithfield Foods, Inc., a Virginia corporation (together with its respective successors and assigns, the
“Issuer”) agrees with you as follows: 
  
 1. PRELIMINARY
STATEMENTS. 
  
 The Issuer issued and sold: 
  
 (a) Nine Million Eight Hundred and Fifty-Two Thousand Nine
Hundred Forty-Two Dollars ($9,852,942) in aggregate principal amount of 8.41% Series B Senior Secured Notes due August 1, 2006 (as they may be amended, restated or otherwise modified from time to time, the “Series B Notes”);

  
 (b) Forty Million Dollars ($40,000,000) in
aggregate principal amount of its 8.34% Series C Senior Secured Notes due August 1, 2003 (as they may be amended, restated or otherwise modified from time to time, the “Series C Notes”); 
  
 (c) Nine Million Dollars ($9,000,000) in aggregate principal
amount of its 9.80% Series D Senior Secured Notes due August 1, 2003 (as they may be amended, restated or otherwise modified from time to time, the “Series D Notes”); 
  
 (d) Nine Million Two Hundred Fifty Thousand Dollars ($9,250,000) in aggregate principal amount of its 10.75%
Series E Senior Secured Notes due August 1, 2005 (as they may be amended, restated or otherwise modified from time to time, the “Series E Notes”); 
  
 (e) One Hundred Million Dollars ($100,000,000) in aggregate principal amount of its 8.52% Series F Senior
Secured Notes due August 1, 2006 (as they may be amended, restated or otherwise modified from time to time, the “Series F Notes”); 
  
 (f) Fourteen Million Dollars ($14,000,000) in aggregate principal amount of its 9.85% Series G Senior Secured Notes due November 1, 2006
(as they may be amended, restated or otherwise modified from time to time, the “Series G Notes”); and 
  
 (g) Fourteen Million Seven Hundred Seventy-Nine Thousand Four Hundred and Twelve Dollars ($14,779,412) in aggregate principal amount of
its 8.41% Series H 

 Senior Secured Notes due August 1, 2004 (as they may be amended, restated or otherwise modified from time
to time, the “Series H Notes” and, together with the Series B Notes, the Series E Notes, the Series F Notes and the Series G Notes, collectively, the “Notes”); 
  
 pursuant to those separate Amended and Restated Note Purchase Agreements each dated as of
October 31, 1999 among the Issuer and the noteholders named in Annex 1 thereto (as amended by that certain Amendment Agreement No. 1, dated as of December 7, 2001, that certain Amendment Agreement No. 2, dated as of December 31, 2002, that certain
Amendment Agreement No. 3, dated as of April 4, 2003 and that certain Amendment Agreement No. 4, dated as of October 31, 2003, each among the Issuer and the other parties listed on the signature pages thereto, the “Existing Purchase
Agreements”). The register kept by the Issuer for the registration and transfer of the Notes indicates that each of the Persons named in Annex 1 hereto (collectively, the “Current Holders”) is currently a holder of the
outstanding aggregate principal amount of the Notes as of the date hereof indicated in such Annex. The Series C Notes and the Series D Notes became due and all then outstanding principal and interest thereon was paid in full on August 1, 2003.

  
 In connection with the Issuer’s agreement to sell its
Canadian subsidiaries to Maple Leaf Foods, Inc. (the “Transaction”), the Required Holders previously agreed to amend the Existing Purchase Agreements to exclude certain effects of the Transaction from certain of the restrictions set
forth in Section 6.15 of the Existing Purchase Agreements relating to Transfers of Property by the Issuer and its Subsidiaries. Such exclusion is contingent upon certain conditions, including the consummation of the Transaction on or before April 1,
2004. Due to pending regulatory approvals, the Issuer has requested that the Current Holders extend such date until April 30, 2004. 
  
 2. DEFINED TERMS. 
  
 Capitalized terms used herein and not otherwise defined herein have the meanings ascribed to them in the Existing Purchase Agreements. 
  
 3. AMENDMENT TO EXISTING PURCHASE AGREEMENTS. 
  
 The Required Holders and the Issuer hereby agree to amend clause (e) of the
definition of “Smithfield Canada Transfer Conditions” set forth in Section 9.1 of the Existing Purchase Agreements by deleting the phrase, “such Transfer is consummated on or before April 1, 2004”, and substituting in its place
the phrase, “such Transfer is consummated on or before April 30, 2004”. Such amendment is referred to herein as the “Amendment”. 
  
 4. CONSENT. 
  
 The Required Holders hereby consent to the execution and delivery of amendments to those certain separate Note Purchase Agreements, dated as of March 1,
2002, between the Issuer and each of the purchasers listed on Annex 1 thereto, those certain separate Note Purchase Agreements, dated as of June 2, 2000 between the Issuer and each of the purchasers listed on Annex 1 thereto, and those certain
separate Amended and Restated Note Purchase Agreements, dated as of October 27, 1999, between the Issuer and each of the purchasers listed on Annex 1 thereto. Each such amendment shall be substantially in the form of this Amendment Agreement.

  

 2 

 5. EXPENSES. 
  
 Whether or not the Amendment becomes effective, the Issuer will promptly (and in any event within thirty (30) days of receiving any statement or invoice
therefor) pay all fees, expenses and costs relating to this Amendment Agreement, including, but not limited to, the reasonable fees of your special counsel, Bingham McCutchen LLP, incurred in connection with the preparation, negotiation and delivery
of this Amendment Agreement and any other documents related thereto. Nothing in this Section 5 shall limit the Issuer’s obligations pursuant to Section 1.4 of the Existing Purchase Agreements. 
  
 6. MISCELLANEOUS. 
  

	 	6.1.	Part of Existing Purchase Agreements; Future References, etc. 

  
 This Amendment Agreement shall be construed in connection with and as a part of the Existing Purchase Agreements and, except as expressly amended by this
Amendment Agreement, all terms, conditions and covenants contained in the Existing Purchase Agreements are hereby ratified and shall be and remain in full force and effect. Any and all notices, requests, certificates and other instruments executed
and delivered after the execution and delivery of this Amendment Agreement may refer to the Existing Purchase Agreements without making specific reference to this Amendment Agreement, but nevertheless all such references shall include this Amendment
Agreement unless the context otherwise requires. 
  

	 	6.2.	Counterparts. 

  
 This Amendment Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one
instrument. Each counterpart may consist of a number of copies hereof, each signed by less than all, but together signed by all, of the parties hereto. Delivery of a facsimile of an executed signature page hereto shall be effective as delivery of an
original. 
  

	 	6.3.	Governing Law. 

  
 THIS AMENDMENT AGREEMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE LAW OF THE
COMMONWEALTH OF VIRGINIA EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH COMMONWEALTH THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH COMMONWEALTH. 
  
 [Remainder of page intentionally left blank. Next page is signature
page.] 
  

 3 

 If you are in agreement with the foregoing, please so indicate by signing the acceptance below on the
accompanying counterpart of this Amendment Agreement and returning it to the Issuer, whereupon it will become a binding agreement among you and the Issuer. 
  

			
	SMITHFIELD FOODS, INC.
		
	 By:
	 	 /s/ Daniel G. Stevens

	 Name:
	 	 Daniel G. Stevens

	 Title:
	 	 Vice President and Chief Financial Officer

  

 [Signature Page to Amendment Agreement No. 5 (B-H)] 

 The foregoing Amendment Agreement is hereby accepted as of the date first above written. 
  

			
	JOHN HANCOCK LIFE INSURANCE COMPANY
		
	 By:
	 	 /s/ Kenneth Warlick

	 Name:
	 	 Kenneth Warlick

	 Title:
	 	 Managing Director

	
	JOHN HANCOCK VARIABLE LIFE INSURANCE COMPANY
		
	 By:
	 	 /s/ Kenneth Warlick

	 Name:
	 	 Kenneth Warlick

	 Title:
	 	 Authorized Signatory

	
	SIGNATURE 6 LIMITED
	By:	 	John Hancock Life Insurance Company, as Portfolio Advisor
		
	 By:
	 	 /s/ Kenneth Warlick

	 Name:
	 	 Kenneth Warlick

	 Title:
	 	 Authorized Signatory

	
	MELLON BANK, N.A., solely in its capacity as Trustee for the BELL ATLANTIC MASTER TRUST, and not in its individual capacity
		
	By:	 	John Hancock Life Insurance Company, as purchaser of all of the Series F Senior Notes owned by such person (re-registration pending)
		
	 By:
	 	 /s/ Kenneth Warlick

	 Name:
	 	 Kenneth Warlick

	 Title:
	 	 Managing Director

	
	JPMORGAN CHASE BANK, as Directed Trustee for the AT&T LONG-TERM INVESTMENT TRUST
		
	 By:
	 	 /s/ Robert M. Lauer

	 Name:
	 	 Robert M. Lauer

	 Title:
	 	 Vice President

  

 [Signature Page to Amendment Agreement No. 5 (B-H)] 

			
	THE MARITIME LIFE ASSURANCE COMPANY
		
	By:	 	  

	Name:	 	 
	Title:	 	 
		
	By:	 	  

	Name:	 	 
	Title:	 	 
	
	METROPOLITAN LIFE INSURANCE COMPANY
		
	By:	 	 /s/ Timothy L. Powell

	Name:	 	Timothy L. Powell
	Title:	 	Director
	
	METLIFE INVESTORS USA INSURANCE COMPANY
	By:	 	Metropolitan Life Insurance Company, as Investment Manager
		
	By:	 	 /s/ Timothy L. Powell

	Name:	 	Timothy L. Powell
	Title:	 	Director
	
	AMERICAN GENERAL LIFE AND ACCIDENT INSURANCE COMPANY
	(successor by merger to The Independent Life and Accident Insurance Company)
	THE VARIABLE ANNUITY LIFE INSURANCE COMPANY
	By:	 	AIG Global Investment Corp., Investment Adviser
		
	By:	 	 /s/ Peter DeFazio

	Name:	 	Peter DeFazio
	Title:	 	Vice President
	
	MONUMENTAL LIFE INSURANCE COMPANY,
	successor by merger to PEOPLES SECURITY LIFE INSURANCE COMPANY
		
	By:	 	 /s/ William J. Hendricksen

	Name:	 	William J. Hendricksen
	Title:	 	Vice President
	
	MASSACHUSETTS MUTUAL LIFE INSURANCE COMPANY
	By:	 	David L. Babson & Company, Inc., as Investment Adviser
		
	By:	 	 /s/ Kathleen Lynch

	Name:	 	Kathleen Lynch
	Title:	 	Managing Director

  

 [Signature Page to Amendment Agreement No. 5 (B-H)] 

 The undersigned consent to the Amendments effected by the foregoing Amendment Agreement. 
  
 CODDLE ROASTED MEATS, INC. 
 GWALTNEY OF SMITHFIELD, LTD. 
 HANCOCK’S OLD FASHIONED COUNTRY
HAM, INC. 
 IOWA QUALITY MEATS, LTD. 
 JOHN MORRELL
& CO. 
 LYKES MEAT GROUP, INC. 
 MOYER PACKING
COMPANY 
 NORTH SIDE FOODS CORP. 
 PACKERLAND
HOLDINGS, INC. 
 PACKERLAND PROCESSING COMPANY, INC. 
 PACKERLAND-PLAINWELL, INC. (f/k/a Murco Foods, Inc.) 
 PATRICK CUDAHY INCORPORATED 
 PREMIUM PORK, INC. 
 QUIK-TO-FIX FOODS, INC. 
 SFFC, INC. 
 SMITHFIELD PURCHASE CORPORATION (successor by merger to
Carroll’s Realty, Inc.) 
 STADLER’S COUNTRY HAMS, INC. 
 SUN LAND BEEF COMPANY 
 SUNNYLAND, INC. 
 THE SMITHFIELD COMPANIES, INC. 
 THE SMITHFIELD PACKING COMPANY INCORPORATED 
  

			
	MURPHY-BROWN LLC
	 By:
	 	 John Morrell & Co., as sole member

  

			
	MURPHY FARMS LLC
	QUARTER M FARMS LLC
	CARROLL’S FOODS OF VIRGINIA LLC
	CARROLL’S FOODS LLC
	CIRCLE FOUR LLC
	CENTRAL PLAINS FARMS LLC
	BROWN’S OF CAROLINA LLC
	 By:
	 	 Murphy-Brown LLC, as sole member

	 By:
	 	 John Morrell & Co., as sole member

	
	BROWN’S FARMS, LLC
	 By:
	 	 Brown’s of Carolina LLC, as sole member

	 By:
	 	 Murphy-Brown LLC, as sole member

	 By:
	 	 John Morrell & Co., as sole member

	
	CARROLL’S REALTY PARTNERSHIP
	 By:
	 	 Smithfield Purchase Corporation, as general partner

	
	SMITHFIELD PACKING REAL ESTATE, LLC
	 By:
	 	 The Smithfield Packing Company Incorporated, as sole member

	
	GREAT LAKES CATTLE CREDIT COMPANY, LLC
	 By:
	 	 Packerland Holdings, Inc., as sole member

  

 [Signature Page to Amendment Agreement No. 5 (B-H)] 

			
	SMITHFIELD-CARROLL’S FARMS
	 By:
	 	 Smithfield Purchase Corporation, as general partner

	
	BROWN’S REALTY PARTNERSHIP
	 By:
	 	 Brown’s Farms, LLC, its partner

	 By:
	 	 Brown’s of Carolina LLC, its sole member and manager

	 By:
	 	 Murphy-Brown LLC, its sole member and manager

	 By:
	 	 John Morrell & Co., as sole member and

	 By:
	 	 Smithfield Purchase Corporation, its partner

	
	SMITHFIELD PACKING REALTY PARTNERSHIP
	 By:
	 	 Smithfield Packing Real Estate, LLC, its partner

	 By:
	 	 The Smithfield Packing Company, Incorporated, its sole member and manager and

	 By:
	 	 Smithfield Purchase Corporation, its partner

		
	 By:
	 	 /s/ Daniel G. Stevens

	 Name:
	 	 Daniel G. Stevens

	 Title:
	 	 Vice President

  

 [Signature Page to Amendment Agreement No. 5 (B-H)] 

 ANNEX 1 
  
 CURRENT HOLDERS AND PRINCIPAL AMOUNTS 
 As of March 25, 2004 
  

																
	 Name of Current Holder

	  	Aggregate
Principal
Amount of
Series B
Notes Held

	  	Aggregate
Principal
Amount of
Series E
Notes Held

	  	Aggregate
Principal
Amount of
Series F Notes
Held

	  	 Aggregate
Principal
Amount of
Series G
 Notes Held

	  	Aggregate
Principal
Amount of
Series H
Notes Held

	John Hancock Life Insurance Company	  	$	7,578,942	  	$	1,500,000	  	$	24,000,000	  	$	3,666,666.77	  	$	-0-
	John Hancock Variable Life Insurance Company	  	$	-0-	  	$	-0-	  	$	5,000,000	  	$	-0-	  	$	-0-
	Signature 6 Limited	  	$	-0-	  	$	-0-	  	$	2,040,000	  	$	-0-	  	$	-0-
	Mellon Bank, N.A., Trustee under Master Trust Agreement of Bell Atlantic Master Trust	  	$	-0-	  	$	-0-	  	$	3,000,000	  	$	-0-	  	$	-0-
	Mellon Bank, N.A. Trustee under Master Trust Agreement of Long-Term Investment Trust	  	$	-0-	  	$	-0-	  	$	960,000	  	$	-0-	  	$	-0-
	The Maritime Life Assurance Company	  	$	-0-	  	$	-0-	  	$	5,000,000	  	$	-0-	  	$	-0-
	Metropolitan Life Insurance Company (as assignee of The Northwestern Mutual Life Insurance Company)	  	$	-0-	  	$	-0-	  	$	20,000,000	  	$	-0-	  	$	-0-
	MetLife Investors USA Insurance Company (as assignee of The Northwestern Mutual Life Insurance Company)	  	$	-0-	  	$	-0-	  	$	10,000,000	  	$	-0-	  	$	-0-
	American General Life and Accident Insurance Company (Successor by merger to Independent Life and Accident Insurance Company)	  	$	-0-	  	$	-0-	  	$	3,000,000	  	$	-0-	  	$	-0-
	The Variable Annuity Life Insurance Company	  	$	-0-	  	$	-0-	  	$	12,000,000	  	$	-0-	  	$	-0-
	Monumental Life Insurance Company, Successor by Merger to Peoples Security Life Insurance Company	  	$	-0-	  	$	-0-	  	$	12,500,000	  	$	-0-	  	$	-0-
	Massachusetts Mutual Life Insurance Company	  	$	-0-	  	$	-0-	  	$	2,500,000	  	$	-0-	  	$	7,389,706
	 	  	
	
	  	
	
	  	
	
	  	
	
	  	
	

	 Total
	  	$	7,578,942	  	$	1,500,000	  	$	100,000,000	  	$	3,666,666.77	  	$	7,389,706
	 	  	
	
	  	
	
	  	
	
	  	
	
	  	
	

  

 Exhibit B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]